Trifecta™ Durability Study

NCT ID: NCT01256710

Last Updated: 2023-11-22

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

1151 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-01-31

Study Completion Date

2021-03-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Trifecta™ Durability Study was a multi-center, prospective, single-arm, post-market study conducted in Europe and Canada to collect long-term safety and performance data on the Trifecta™ valve. The Trifecta™ valve is a stented surgical aortic bioprosthesis with bovine pericardial leaflets designed for supra annular placement.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aortic Valve Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Trifecta™ Valve Group

Subjects implanted with the Trifecta™ aortic bioprosthesis.

Trifecta™ aortic bioprosthesis

Intervention Type DEVICE

Surgical aortic valve replacement with the Trifecta™ valve.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Trifecta™ aortic bioprosthesis

Surgical aortic valve replacement with the Trifecta™ valve.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients implanted for less than 9 months with a Trifecta™ valve, or patients who are candidates for implant with a Trifecta™ valve, as per current guidelines
* Patient requires aortic valve replacement.
* Patient is legal age in host country.
* Patients must be able and willing to provide written informed consent to participate in this investigation
* Patients must be willing and able to comply with all follow-up requirements

Exclusion Criteria

* Patients with contraindication for cardiac surgery
* Patients who are pregnant.
* Patient is unwilling to or has an inability that reduces his mobility in order to attend the required follow-up visits.
* Patient has active endocarditis
* Patient has had an acute preoperative neurological event defined as patient has not returned to baseline 30 days prior to the planned valve implantation surgery.
* Patient is undergoing renal dialysis.
* Patient has a documented history of substance abuse within one year of enrollment or is currently a prison inmate.
* Patient has a documented thrombus in left atrium or left ventricle.
* Patient had in the past mitral or tricuspid valve replacement.
* Patient needs mitral and/or tricuspid valve replacement.
* Patient has an Ejection Fraction \< 25%
* Patient had the Trifecta™ valve implanted as part of this study, but then had the device explanted
* Preoperative evaluation indicates other significant cardiovascular abnormalities such as aortic dissection or ventricular aneurysm.
* Patient has a life expectancy less than two years.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Abbott Medical Devices

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sven Lehmann

Role: PRINCIPAL_INVESTIGATOR

Universitat Herzzentrum Leipzig

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Universitat Herzzentrum Leipzig

Leipzig, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CS-10-012-EU-TV

Identifier Type: -

Identifier Source: org_study_id